Publication | Open Access

A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer

MedicineImmunologyBronchial NeoplasmImmune Checkpoint InhibitorFirst-line TreatmentPhase Ib/ii StudyCancer TreatmentImmunotherapyOncologyRadiation OncologyLung Cancer